0102030405
Nilotinib CAS No. 641571-10-0 Antineoplastic Pharmaceutical Raw Material
02
introduce
introduce
Nilotinib is a potent oral tyrosine kinase inhibitor (TKI) and core antineoplastic API, designed as a second-generation inhibitor of Bcr-Abl fusion protein. It exhibits high affinity for Bcr-Abl (including imatinib-resistant mutants), blocking tumor cell proliferation and survival.
Our products comply with strict international standards to ensure high purity, stable efficacy, and reliable supply for clinical use and biomedical research.
02
Physical and chemical properties
Nilotinib exhibits key physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Density: 1.4±0.1 g/cm³
- Melting Point: 231-233 °C
- Storage Temperature: -20°C Freezer
- Solubility: Soluble in DMSO (50 mg/ml)
- Density: 1.4±0.1 g/cm³
- Melting Point: 231-233 °C
- Storage Temperature: -20°C Freezer
- Solubility: Soluble in DMSO (50 mg/ml)
1. Stronger Inhibitory Activity and Target Selectivity
As a second-generation tyrosine kinase inhibitor improved from imatinib's molecular structure, its inhibitory effect on BCR-ABL kinase is 30 times that of imatinib, and it can more precisely stabilize the inactive conformation of ABL kinase. Meanwhile, it can inhibit the activity of imatinib-resistant BCR-ABL mutant kinases, solving the clinical problem of imatinib resistance.
As a second-generation tyrosine kinase inhibitor improved from imatinib's molecular structure, its inhibitory effect on BCR-ABL kinase is 30 times that of imatinib, and it can more precisely stabilize the inactive conformation of ABL kinase. Meanwhile, it can inhibit the activity of imatinib-resistant BCR-ABL mutant kinases, solving the clinical problem of imatinib resistance.
2. More Comprehensive Target Coverage
In addition to the core inhibition of BCR-ABL kinase, it can also inhibit the activity of KIT and PDGFR kinases. Compared with single-target drugs that only act on BCR-ABL, it has a wider range of applications and can cope with the proliferation of more tumor cells dependent on related kinases.
In addition to the core inhibition of BCR-ABL kinase, it can also inhibit the activity of KIT and PDGFR kinases. Compared with single-target drugs that only act on BCR-ABL, it has a wider range of applications and can cope with the proliferation of more tumor cells dependent on related kinases.
3. Significant Clinical Efficacy for Resistant Patients
For imatinib-resistant Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) patients in the chronic phase, 42% of patients experienced reduction or disappearance of abnormal chromosomes after medication; for patients in the accelerated phase, 31% of patients achieved the same effect, with efficacy far superior to traditional treatment regimens.
1. Core Indication
Used for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), especially suitable for patients in the chronic and accelerated phases who are resistant or intolerant to imatinib.
2. Potential Application Value
Relevant clinical trials are underway, and it is expected to be used for the treatment of acute lymphoblastic leukemia (ALL) and gastrointestinal stromal tumors (GISTs), expanding the application scenarios of tumor targeted therapy.
Used for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), especially suitable for patients in the chronic and accelerated phases who are resistant or intolerant to imatinib.
2. Potential Application Value
Relevant clinical trials are underway, and it is expected to be used for the treatment of acute lymphoblastic leukemia (ALL) and gastrointestinal stromal tumors (GISTs), expanding the application scenarios of tumor targeted therapy.
We implement strict full-process quality control, with each batch of Nilotinib undergoing rigorous testing of key indicators including purity, solubility, stability, enantiomeric excess, and biological activity to meet standards.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and research needs.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and research needs.
As a second-generation Bcr-Abl tyrosine kinase inhibitor, Nilotinib has become a pivotal therapy for chronic myeloid leukemia, offering enhanced efficacy for imatinib-resistant patients. With its high target specificity, proven clinical benefits, exceptional quality, and reliable supply capacity, we are committed to providing high-quality Nilotinib API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Nilotinib to meet your needs in pharmaceutical formulation, oncology research, and clinical treatment. Contact us for more product details and cooperation support.
Choose our Nilotinib to meet your needs in pharmaceutical formulation, oncology research, and clinical treatment. Contact us for more product details and cooperation support.